Related Experiment Video

Updated: Feb 16, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K

Early intervention for infants and toddlers: Applications for pediatric oncology

Jennifer L Harman1, Jillian Wise1, Victoria W Willard1

  • 1Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Pediatric Blood & Cancer
|December 23, 2017
PubMed

Insights

Pediatric cancer patients under 3 years old often experience developmental delays. Early Intervention (EI) services can help, but children with cancer are seldom referred, impacting long-term outcomes.

Area of Science:

  • Pediatric oncology
  • Developmental pediatrics
  • Early intervention services

Background:

  • Young children (<3 years) with cancer face significant risks for developmental delays.
  • These delays stem from the disease itself, cancer treatments, and necessary health restrictions.
  • Early Intervention (EI) services are crucial for addressing developmental delays in young children.

Purpose of the Study:

  • To highlight the critical impact of early childhood development on long-term outcomes for pediatric cancer patients.
  • To review current considerations and eligibility criteria for Early Intervention services.
  • To advocate for increased referrals of young children with cancer to Early Intervention programs.

Main Methods:

  • Literature review on early childhood development in the context of pediatric cancer.
  • Analysis of the Individuals with Disabilities Education Act (IDEA) Part C regulations regarding EI services.
  • Examination of referral patterns for EI services among young children diagnosed with cancer.

Main Results:

  • Children with cancer are identified as a population at high risk for developmental delays.
  • Despite potential eligibility, referral rates for EI services for these children are notably low.
  • Developmental delays in early childhood can have profound and lasting effects on overall outcomes.

Conclusions:

  • Early Intervention is vital for mitigating developmental deficits in young children with cancer.
  • Systematic referral to EI services is necessary to support the developmental trajectory of these vulnerable children.
  • Increased awareness and advocacy are needed to ensure access to EI for all eligible pediatric cancer patients.

Keywords:
childhood cancerearly childhood developmentearly interventioninfants and toddlers

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
337
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
323
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K